Innovative Asset Advisors Group’s VanEck Biotech ETF BBH Stock Holding History

Innovative Asset Advisors Group’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-75	Closed	-$14.1K	–	346
2026 Q1	$14.1K	Buy	+75	New	+$14.5K	0.01%	575

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Innovative Asset Advisors Group's BBH Position: Q2 2026 in Review

Innovative Asset Advisors Group sold out of VanEck Biotech ETF (BBH) in Q2 2026, closing a stake of 75 shares — an estimated $14.1K sold.

Innovative Asset Advisors Group first reported a position in BBH in Q1 2026 and held it in 1 quarter. The position peaked at $14.1K in Q1 2026. 110 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

Innovative Asset Advisors Group reported no remaining VanEck Biotech ETF position as of Q2 2026 after selling out during the quarter.
Innovative Asset Advisors Group sold 75 VanEck Biotech ETF shares in Q2 2026, an estimated $14.1K.
Innovative Asset Advisors Group first reported a position in VanEck Biotech ETF in Q1 2026 and held it in 1 quarter.
Innovative Asset Advisors Group's VanEck Biotech ETF position peaked at $14.1K in Q1 2026.
110 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Innovative Asset Advisors Group's 13F filing for Q2 2026, filed 5 Aug 2026.